Flat-Rate Subscription to In-Depth Publishing Reports on Oncology, Biosimilars, Antibodies, Proteins and Vaccines - FOX5 Vegas - KVVU

Flat-Rate Subscription to In-Depth Publishing Reports on Oncology, Biosimilars, Antibodies, Proteins and Vaccines

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, February 26, 2014 /PRNewswire/ --

Dublin - Research and Markets (http://www.researchandmarkets.com/research/h27svw/flatrate) has announced the addition of the "Flat-Rate Subscription to In-Depth Publishing Reports on Oncology, Biosimilars, Antibodies, Proteins and Vaccines" subscription to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


Subscription to this product provides access during one year to all existing and new reports produced by La Merie Publishing and listed in the online store. Among these reports are Competitor Analysis reports as well as Full Reports. La Merie Publishing reports are continuously updated and new ones released. Reports can be searched for and identified in La Merie Publishing's online store. After purchase of the product, existing reports will be made available to the customer by e-mail delivery of the pdf reports. 

Examples of Full Reports

  • Antibody Technologies and Attrition Rates - an industry analysis 2013
  • Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012
  • Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
  • Coagulation Factors 2011 - who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis
  • Antibody Technology Companies 2010

Examples of Oncology Reprots

  • Antibody-Drug Conjugates (ADC)
  • c-MET/HGF Inhibitors
  • HDAC Inhibitors
  • Janus Kinase (JAK) Inhibitors
  • Novel Mitotic Kinase Inhibitors
  • PARP Inhibitors
  • PI3K-AKT-mTOR Inhibitors
  • Ras-Raf-MEK-ERK Inhibitors

Examples of Biosimilar & Biosuperior Protein Reports

  • Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
  • Erythropoiesis Stimulating Agents (ESA)
  • Coagulation Factors
  • G-CSF and GM-CSF
  • Enzyme Replacement Therapies
  • FSH, LH & hCG: Assisted Reproductive Technologies (ART)
  • Interferon
  • Thrombopoiesis Stimulating Agents
  • Insulin
  • Human Growth Hormone
  • Thrombolytic Agents

Examples of Biosimilar & Biosuperior Antibody Reports

  • Biosimilar and Biosuperior Therapeutic Antibodies
  • CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
  • Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors
  • VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors
  • EGF-R Antibodies -Biosimilars and Biosuperiors
  • TNF Antibodies - Biosimilars and Biosuperiors

Examples of Vaccine Reports

  • Herpes Virus Vaccines and Therapeutics
  • Pneumococcal and Streptococcal Vaccines
  • Tuberculosis Vaccines and Therapeutics
  • Malaria Vaccines & Therapeutics
  • CMV Vaccines & Therapeutics
  • Dengue Virus Vaccines & Therapeutics
  • RSV Vaccines & Therapeutics
  • Pseudomonar Aeruginosa Vaccines & Therapeutics
  • Staphylococcus aureus Vaccines & Therapeutics
  • Cancer Vaccines
  • HIV Vaccines
  • Hepatitis Vaccines
  • Influenza Vaccines
  • HPV Vaccines
  • Anthrax Vaccines & Therapeutics

Examples of Other Popular Reports

  • Toll-Like Receptor (TLR) Agonists & Antagonists
  • Cardiovascular Peptides


For more information visit http://www.researchandmarkets.com/research/h27svw/flatrate


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
Fox 5
Powered by WorldNow CNN
All content © 2014, KVVU Broadcasting Corporation, Las Vegas, NV and WorldNow. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service..